Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded Phase I./II Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant

NCT06824519 is registered in ClinicalTrials.gov with Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. as lead sponsor.

NCT NCT06824519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06824519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded Phase I./II Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant
Lead sponsor
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 8, 2025
Completion date
September 30, 2026
Enrollment
620 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human